Intra-Cellular Therapies Inc
NASDAQ:ITCI
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
64.37
91.57
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Intra-Cellular Therapies Inc
Intra-Cellular Therapies Inc
Other Non-Cash Items
Intra-Cellular Therapies Inc
Other Non-Cash Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Non-Cash Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Intra-Cellular Therapies Inc
NASDAQ:ITCI
|
Other Non-Cash Items
$54.1m
|
CAGR 3-Years
27%
|
CAGR 5-Years
24%
|
CAGR 10-Years
36%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Non-Cash Items
$3.5B
|
CAGR 3-Years
37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Non-Cash Items
$14.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
90%
|
CAGR 10-Years
80%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Non-Cash Items
$6.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
35%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Non-Cash Items
$5.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
12%
|
CAGR 10-Years
27%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Non-Cash Items
$4.5B
|
CAGR 3-Years
46%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
26%
|
|
Intra-Cellular Therapies Inc
Glance View
Intra-Cellular Therapies Inc., founded in 2002, finds itself at the intersection of scientific innovation and commercial success. This biopharmaceutical company is built around the vision of translating ground-breaking discoveries in neuroscience into important medications for serious neuropsychiatric and neurological disorders. The firm’s flagship product, CAPLYTA (lumateperone), exemplifies its dedication to comprehensive central nervous system solutions. Approved by the FDA for the treatment of schizophrenia in adults, and later approved for bipolar depression, CAPLYTA positions Intra-Cellular Therapies within a competitive landscape of mental health treatments. It is through pharmaceutical sales of CAPLYTA that Intra-Cellular Therapies generates revenue, capitalizing on extensive research to carve out a niche in a market with significant medical needs. Operating predominantly in the United States, Intra-Cellular Therapies harnesses its proprietary technologies, including PDE1 inhibition and other novel mechanisms of action, to pioneer treatments aimed at improving patients' quality of life. The company invests heavily in research and development, fueled by its robust clinical pipeline that constantly explores new therapeutic opportunities. Their approach involves not just the development of medications but also extensive engagement with healthcare providers and thought leaders to better understand and serve the patient community. This strategy underscores a business model where innovation directly translates to market viability, as the company embarks on long-term growth through the expansion of indications for its existing drugs and exploration of new compounds.
See Also
What is Intra-Cellular Therapies Inc's Other Non-Cash Items?
Other Non-Cash Items
54.1m
USD
Based on the financial report for Sep 30, 2024, Intra-Cellular Therapies Inc's Other Non-Cash Items amounts to 54.1m USD.
What is Intra-Cellular Therapies Inc's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 10Y
36%
Over the last year, the Other Non-Cash Items growth was 21%. The average annual Other Non-Cash Items growth rates for Intra-Cellular Therapies Inc have been 27% over the past three years , 24% over the past five years , and 36% over the past ten years .
You don't have any saved screeners yet
